NEUP
Neuphoria·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
NEUP Profile
Neuphoria Therapeutics Inc.
A clinical stage biopharmaceutical company focused on developing treatment methods for brain diseases
100 Summit Drive, Burlington, Massachusetts 01803
Biopharmaceutical
Neuphoria Therapeutics Inc. (formerly Bionomics Limited) was incorporated under the laws of Australia in 1996 and relocated to Delaware and became a domestic company on December 24, 2024. As a clinical-stage biotechnology company, it develops treatments for neuropsychiatric disorders. Its lead drug candidate, BNC 210 (Oral Selective α7 Nicotinic ACH Receptor Modulator), targets acute SAD and chronic PTSD, with an unmet need in more than 27 million U.S. patients. BNC 210 is a pioneering anti-anxiety therapy that quickly restores neurotransmitter balance without sedation, cognitive problems or addiction. It has a partnership with Merck (outside the US/Canada) for two early-stage clinical CNS drugs. Its pipeline includes next-generation α7 receptors and KV 3.1/3.2 preclinical programs (pilot optimization). Current treatments (antidepressants, benzodiazepines) have lacked new FDA approval for decades and are flawed; BNC 210 has shown rapid action and no restrictive side effects in trials.
